Overview
NXTC market data
Price History
NXTC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.55 – $15.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $17.3 · P/B 1.42 · P/S 0.63.
Company news
Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 15, 2026, 8:32 AM
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its ShareholdersGlobenewswire Inc · Jul 14, 2026, 11:15 PM
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis TherapyBenzinga · Jul 14, 2026, 6:09 PM
Dow Falls Over 100 Points Following Inflation Data; Crude Oil GainsBenzinga · Jul 14, 2026, 4:50 PM
Nasdaq Surges Over 100 Points; Bank of America Earnings Top ViewsBenzinga · Jul 14, 2026, 2:05 PM
NextCure shares are trading higher after the company announced a merger with Avere Therapeutics.Benzinga · Jul 14, 2026, 11:29 AM
8-K filing — NextCure, Inc. (NXTC)SEC EDGAR · Jul 14, 2026, 11:00 AM
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyGlobenewswire Inc · Jul 14, 2026, 11:00 AM
NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private PlacementBenzinga · Jul 14, 2026, 10:05 AM
What's Going On With NextCure Stock Wednesday?Benzinga · Jun 3, 2026, 2:30 PM